Evoke Wealth LLC Grows Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

Evoke Wealth LLC grew its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 207.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 192,926 shares of the company’s stock after purchasing an additional 130,186 shares during the quarter. Evoke Wealth LLC owned approximately 0.33% of Inari Medical worth $9,849,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Vestal Point Capital LP boosted its stake in Inari Medical by 342.9% in the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after purchasing an additional 1,200,000 shares during the period. Jennison Associates LLC lifted its position in Inari Medical by 63.2% in the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after buying an additional 610,468 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Inari Medical by 101.3% in the third quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company’s stock worth $32,790,000 after buying an additional 400,198 shares during the last quarter. Bamco Inc. NY lifted its position in shares of Inari Medical by 29.5% during the third quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock worth $41,493,000 after purchasing an additional 228,977 shares during the last quarter. Finally, Point72 DIFC Ltd bought a new stake in shares of Inari Medical during the third quarter worth $9,008,000. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $79.97 on Tuesday. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $79.99. The company has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. The business has a 50 day moving average of $79.76 and a two-hundred day moving average of $59.27.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wells Fargo & Company restated an “equal weight” rating and issued a $80.00 price objective (up from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Canaccord Genuity Group reiterated a “hold” rating and issued a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research report on Wednesday, January 8th. Finally, Oppenheimer began coverage on Inari Medical in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price on the stock. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Inari Medical has a consensus rating of “Hold” and an average target price of $68.00.

Insider Transactions at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the sale, the chief executive officer now directly owns 439,310 shares in the company, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the sale, the director now owns 238,987 shares of the company’s stock, valued at $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.